What is the clinical effectiveness, cost effectiveness and implications for safety of assessing anti-tumour necrosis factor (TNF)α drug levels and antibodies in children with moderate to severe inflammatory bowel disease compared with existing clinical strategies in use in NHS Scotland?
Thompson L
Record ID 32013000490
English
Authors' objectives:
Summary.
Data on the associations between clinical response, development of ATAs and serum levels of anti-TNFα medications are complex and conflicting, and there is a lack of standardisation of assays or outcomes measures. No prospective comparative studies were identified assessing the utility of the measures in directing clinical decision making. Ten ongoing trials were identified.
Authors' recommendations:
Given the large number of trials in progress an evidence review of the primary literature should be conducted in three to five years.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/shtg_scoping_reports/technologies_scoping_report_18.aspx
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Scotland, United Kingdom
MeSH Terms
- Humans
- Inflammatory Bowel Diseases
- Tumor Necrosis Factor-alpha
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
Contact
Organisation Name:
Scottish Health Technologies Group
Contact Address:
Scottish Health Technologies Group, Delta House, 50 West Nile Street, Glasgow, G1 2NP Tel: 0141 225 6998
Contact Name:
his.shtg@nhs.scot
Contact Email:
his.shtg@nhs.scot
Copyright:
Healthcare Improvement Scotland
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.